HRQoL and Efficacy with Myelofibrosis Patients in the Phase III Persist-1 Trial of Pacritinib Vs BAT
At ASH 2015, Dr. Ruben Mesa from Mayo Clinic discussed his poster titled "Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)."
Recent Video
Most Popular
Specialties :                    Search : is a member of the Oncology.TV family of oncology medical education websites. offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).